CD274 and neoplasm: Chimeric antigen receptor (CAR) T cells can also be engineered to secrete PD‐1/PD‐L1 blocking molecules at tumor sites.[271, 272, 273, 274] T cell‐based delivery has demonstrated superior anti‐tumor efficacy and safety than combined cell transfer and checkpoint blockade.[271, 272, 273, 274] Whether these TME‐targeted delivery techniques can be extrapolated into the targeted delivery of ICIs to LNs requires further exploration.